You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human Gm–CSFR-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study

Article metrics

Article menu
Download PDFPDF
Oral Presentations
Abstract session: Developments in the treatment of RA
OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human Gm–CSFR-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study

 

Online download statistics by month:

Online download statistics by month: June 2015 to March 2024

AbstractFullPdf
Jun 20152101
Jul 20152101
Aug 20153503
Sep 20155002
Oct 20152001
Nov 20151701
Dec 20152302
Jan 20162004
Feb 20161400
Mar 20161906
Apr 20162001
May 20161401
Jun 20161601
Jul 20161200
Aug 20161000
Sep 20162602
Oct 20161601
Nov 20161504
Dec 2016700
Jan 20172111
Feb 20171803
Mar 20172902
Apr 20171000
May 20171400
Jun 2017901
Jul 20171301
Aug 2017800
Sep 2017600
Oct 20171001
Nov 20172600
Dec 2017800
Jan 2018800
Feb 2018401
Mar 20182000
Apr 2018600
May 2018601
Jun 2018600
Jul 2018600
Aug 2018800
Sep 2018200
Oct 2018600
Nov 2018200
Dec 2018600
Jan 2019800
Feb 2019400
Mar 2019400
Apr 2019200
May 20191100
Jun 20191700
Jul 20192200
Aug 2019400
Nov 2019300
Dec 20191400
Jan 2020200
Feb 2020203
Apr 2020700
May 20201200
Jun 2020600
Jul 20201601
Aug 2020500
Sep 20203000
Oct 2020600
Nov 20201000
Dec 20201500
Jan 2021400
Feb 2021200
Apr 2021200
May 2021100
Jul 2021101
Oct 2021200
Nov 20211200
Dec 2021800
Jan 2022200
Feb 20221201
Mar 20221002
Apr 20221100
May 20221000
Jun 20221201
Jul 20221400
Aug 20221000
Sep 20221201
Oct 2022600
Nov 2022700
Dec 2022900
Jan 2023300
Feb 2023800
Mar 2023300
Apr 2023300
May 2023501
Jul 2023300
Aug 2023100
Sep 2023400
Oct 2023500
Dec 20231200
Jan 2024500
Feb 2024300
Mar 20241000
Total1040153